Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The luteinizing hormone-choriogonadotropin receptor (LHCGR) is a membrane-bound G protein-coupled receptor that binds both luteinizing hormone (LH) and chorionic gonadotropin (hCG), triggering critical signaling pathways in reproductive tissues. Upon activation by its ligands, LHCGR initiates the cAMP/PKA signaling cascade, ultimately leading to steroidogenesis, ovulation, and spermatogenesis. It is predominantly expressed in the gonads but also found in other reproductive tissues. Mutations in the LHCGR gene are implicated in a variety of reproductive disorders in both sexes, and the receptor is a key therapeutic target for fertility treatments and hormone-responsive cancers
Activation of the LHCGR by hCG or LH stimulates coupling with Gαs protein, activating adenylyl cyclase, which in turn increases intracellular cAMP; downstream activation leads to steroid hormone production, ovulation, and other reproductive processes. Some drugs may act as agonists or antagonists at this receptor
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Luteinizing hormone-choriogonadotropin receptor (LHCGR).